A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT05785767 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05785767
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-30
- Primary completion
- 2027-09-28
- Enrollment
- 149
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.